新型双重COX-2/5-LOX通过基衍生物的抑制活性:一种安全有效的抗炎剂
Roopal Mittal1,2, Shailesh Sharma3, Amit Mittal4,5
1Department of Pharmacy, IK Gujral Punjab Technical University, Jalandhar Punjab, 144601, India.
概括
基化合物C64有效抑制双COX-2/5-LOX酶,提供强大的抗炎活性. 这种新型的双重抑制剂证明了改善的胃安全性,使其成为治疗炎症疾病的有希望的候选人.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 非传染性疾病与由阿拉基酸级联驱动的慢性炎症有关.
- 研究新型化合物对循环氧化酶-2 (COX-2) 和5-脂氧化酶 (5-LOX) 途径的双重抑制对于抗炎药物开发至关重要.
研究的目的:
- 为了评估 chalcone 化合物的抗炎潜力.
- 评估 chalcones 对 COX-2 和 5-LOX 酶的双重抑制活性.
- 确定有前途的基衍生物的体外和体内疗效和安全性.
主要方法:
- 在体外测定使用RAW 264.7巨细胞来确定IC50值并测量COX-1,COX-2,5-LOX,PGE2和LTB4水平.
- 在雄性Wistar大鼠的体内研究中,使用卡拉基南诱导的脚胀和棉花颗粒诱导的颗粒瘤模型.
- 胃,肝脏和脏组织的组织病理学检查,以评估安全性.
主要成果:
- 石化合物C45和C64显示强烈抑制COX-2和5-LOX,IC50值分别为0.092微米和0.136微米.
- 化合物C64在体内表现出显著的抗炎作用,减少了78.28%的脚胀和32.85%的颗粒瘤形成.
- 与传统的抗炎药物相比,C64化合物显示出可比的COX-2选择性与埃托利可西布,以及改善的胃安全性.
结论:
- 石化合物C64被确定为一种强大的新型双重COX-2/5-LOX抑制剂.
- 该化合物在体外和体外模型中表现出显著的抗炎疗效.
- C64呈现出一个有希望的治疗候选人,增强了胃安全性,用于管理炎症性疾病.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
01:19Antiasthma Drugs: Leukotriene Modifiers
271
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
271
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:24Cholinergic Antagonists: Pharmacokinetics
429
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
429
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
552
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
552
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
399
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
399